RT Journal
A1 Kuehn BM
T1 ERlotinib warning
JF JAMA
JO JAMA
YR 2009
FD June 24
VO 301
IS 24
SP 2542
OP 2542
DO 10.1001/jama.2009.859
UL http://dx.doi.org/10.1001/jama.2009.859
AB 
The drug's makers, OSI Pharmaceuticals and Genentech, have also issued a letter to physicians alerting them to postmarketing reports of such adverse events (http://www.fda.gov/medwatch/safety/2009/Tarceva_DHCP_Letter_April09.pdf). According to the letter, some individuals taking erlotinib have developed gastrointestinal tract perforation, including some deaths. Physicians are warned to permanently stop erlotinib therapy in patients who develop a perforation.